Geron Corporation publishes analysis on imetelstat treatment-emergent cytopenias and clinical response in lower-risk myelodysplastic syndromes
Reuters
Dec 08
Geron Corporation publishes analysis on imetelstat treatment-emergent cytopenias and clinical response in lower-risk myelodysplastic syndromes
Geron Corporation published a document analyzing the correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with lower-risk myelodysplastic syndromes. The document includes data from the IMerge trial and examines clinical consequences such as bleeding, infection, and febrile neutropenia. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.